Mild-to-moderate atopic dermatitis is a chronic inflammatory skin disease often localized to the flexural surfaces of the body and usually begins in childhood. This skin disease affects a large percentage of the world's population. Atopic dermatitis, commonly known as eczema, is characterized by dry skin, itching, redness, swelling, vesicle formation, cracking, weeping, crusting, and scaling. Atopic dermatitis is a long-term skin disease, which is classified into different types depending on the skin condition such as allergic contact eczema, contact eczema, dyshidrotic eczema, neurodermatitis, nummular eczema, seborrheic eczema, and stasis dermatitis. Multiple factors responsible for atopic dermatitis include seasonal allergies, low humidity, cold weather, and exposure to harsh soaps and detergents. The medication treatment of the skin disease depends on the pattern, duration, and severity of the skin lesions. According to the American Academy of Dermatology (AAD), the atopic dermatitis that emerges in adults is often different and more severe than infants and children. Except drug therapy, atopic dermatitis is treated with ultraviolet light therapy. The ultraviolet light therapy are of two types, which are ultraviolet A and ultraviolet B. According to Anacor Pharmaceuticals, Inc., atopic dermatitis is estimated to affect about 15% to 20% of children in developed countries. The disease often becomes milder with age.

Factors such as new product launch, large patient population, and rapid growth in population are projected to drive the global mild-to-moderate atopic dermatitis treatment market. According to the United Nations Population Fund (UNFPA), the global human population is growing at a rate of 1.1%. Large pipeline products and climatic change are factors which are estimated to fuel the growth of the market globally during the forecast period. On the other hand, generic competition and stringent regulations for product approvals are the factors which are projected to hinder the market growth in the near future.

The global mild-to-moderate atopic dermatitis treatment market has been segmented by treatment type, route of administration, distribution channel, and geography. In terms of treatment type, the market is classified into drug treatment and radiation treatment. Drug treatment is further sub-segmented into emollients, antihistamines, antibiotics, corticosteroids, and calcineurin inhibitors. Topical corticosteroids are the standard treatment for most patients with atopic dermatitis for more than 60 years. Calcineurin inhibitors are used as second line treatment drug for atopic dermatitis. In terms of route of administration, the market is classified into topical and oral. Oral medications are offered to patients with severe or treatment-resistant eczema. In terms of distribution channel, the market is classified into hospitals pharmacies, retail pharmacies, and online pharmacies.

Geographically, the mild-to-moderate atopic dermatitis treatment market is distributed over North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Globally, North America dominates the market owing to new product innovations, lifestyle changes, and early treatment adoption, which in turn are likely to drive the growth of the market. A large proportion of the U.S. population has symptoms of eczema. According to the National Eczema Association in the U.S., 31.6 million people are living with eczema, and the prevalence rate of childhood eczema is 10.7%. Europe is the second leading market for mild-to-moderate atopic dermatitis treatment due to large research and development activities. The Asia Pacific market is expected to grow at a higher rate owing to rapid population growth, large target patient pool, changing lifestyle, adoption of western lifestyle, and growth in research and development. These factor are likely to drive the market growth during the forecast period.

The major players operating in this market include Astellas Pharma Inc., Sanofi S.A., Valeant Pharmaceuticals International, Inc., Novartis International AG, Pfizer Inc., Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., and Anacor Pharmaceuticals, Inc. 

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Mild To Moderate Atopic Dermatitis Treatment Market

Pre Book